Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of b…
Biotechnology
US, Vancouver [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Absci Corporation's gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | - | -1.900 | - | 5 | - | -174 | - | -5 | - | -5 | - | 22 |
| 2022 | -1.0900 | -1.166 | 4 | 9 | -100 | -107 | -99 | -9 | -81 | -9 | 28 | 41 |
| 2023 | -1.1500 | -1.083 | 5 | 6 | -104 | -100 | -91 | -6 | -119 | -6 | 40 | 28 |
| 2024 | -1.2000 | -0.847 | 5 | 6 | -110 | -77 | -95 | -6 | -163 | -6 | 37 | 27 |
| 2025 | - | -0.746 | - | 16 | - | -69 | - | -16 | - | -16 | - | 74 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |